Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.

Kamrine E PoelsAdam J SchoenfeldAlex MakhninYosef Y TobiYuli WangHeidie Frisco-CabanosShaon ChakrabartiManli ShiChelsi NapoliThomas O McDonaldWeiwei TanAaron HataScott L WeinrichHelena A YuFranziska Michor

Published in: Nature communications (2022)

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
phase iii
study protocol
phase ii
clinical trial
bioinformatics analysis
wild type
open label